Walsh and colleagues first proposed modifying the existing PM1 pathogenic evidence criterion to apply to germline variants in cancer predisposition genes that overlap with cancer mutations from Cancer Hotspots, [13] provided the variant was not already in a germline hotspot [4]. This evidence concerns the gene TMEM11 and cancer.